BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Multiple sclerosis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for multiple sclerosis: 175 (89 sponsors; 27 newly posted in the last 180 days, 6 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 22, rank 22 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 28, Phase 2 43, Phase 3 45, Phase 4 9, N/A 50.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Hoffmann-La Roche23P3 11, NA 2, P4 1, P2 6, P1 340
Novartis Pharmaceuticals NVS29P3 9, NA 13, P2 3, P4 436
Sanofi SNY7P2 1, P3 5, NA 121
TG Therapeutics, Inc. TGTX9P3 4, P2 1, NA 3, P1 102
Biogen BIIB5P3 2, NA 300
Immunic AG IMUX3P2 1, P3 200
Zenas BioPharma (USA), LLC ZBIO3P2 1, P3 200
Bristol-Myers Squibb BMY7P3 1, NA 5, P4 111
Amgen AMGN1P3 101
Biocad1P3 100
Celltrion1P3 101
Coya Therapeutics COYA1P3 101
MediciNova MNOV1P3 101
Oculis OCS new entrant1P3 110
Oils4Cure1P3 100
RVL Pharmaceuticals, Inc.1P3 100
Sandoz1P3 100
AbelZeta Inc. new entrant2P2 1, P1 120
AstraZeneca AZN2P2 1, P1 100
Eli Lilly and Company LLY2P1 210
Genentech, Inc.2P4 1, P1 110
icometrix2NA 201
Jazz Pharmaceuticals JAZZ2P4 1, NA 101
Kyverna Therapeutics KYTX2NA 1, P2 101
Otto Bock Healthcare Products GmbH2NA 210

New-entrant sponsors: Oculis, AbelZeta Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01 est.P2Hope Biosciences Research FoundationNCT06800404 "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"Relapsing Remitting Multiple Sclerosis (RRMS); Multiple Sclerosisactive not recruiting10
2027-01-21 est.P3TG Therapeutics, Inc. TGTXNCT05877963 Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabRelapsing Multiple Sclerosisrecruiting800
2027-02 est.P3CelltrionNCT05906992 A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisRelapsing-remitting Multiple Sclerosisrecruiting512

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-03P3SandozNCT06847724 Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisRelapsing Multiple Sclerosisactive not recruiting183
2026-11 est.P3Immunic AG IMUXNCT05201638 Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisMultiple Sclerosis, Relapsing-Remittingactive not recruiting1100
2026-11 est.P3Immunic AG IMUXNCT05134441 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisMultiple Sclerosisactive not recruiting1121
2026-10-31 est.P3TG Therapeutics, Inc. TGTXNCT07211633 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With RelapsingRelapsing Multiple Sclerosisactive not recruiting360
2026-10-30 est.P1/P2Vidya Therapeutics IncNCT07085507 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS PatientsMultiple Sclerosisrecruiting100
2026-10-22 est.P3Hoffmann-La RocheNCT03523858 A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisProgressive Multiple Sclerosis (PMS)active not recruiting927
2026-09-17P2Hoffmann-La RocheNCT07074886 A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Multiple Sclerosisactive not recruiting193
2026-09-17P2Tiziana Life Sciences LTD TLSANCT06292923 A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsSecondary Progressive Multiple Sclerosiscompleted54
2026-07-22P3Novartis Pharmaceuticals NVSNCT05156281 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)Relapsing Multiple Sclerosisactive not recruiting1007
2026-07-21P3Novartis Pharmaceuticals NVSNCT05147220 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Relapsing Multiple Sclerosisactive not recruiting1000

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "multiple sclerosis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.